Reading this on a mobile device? Try our optimized mobile version here:

November 21, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
  • RFID improves blood monitoring in pilot test
    The Transfusion Medicine RFID Consortium said it has submitted findings to the FDA about a pilot study of a radio frequency identification blood-monitoring system in support of an application for 510(k) clearance. The system helped increase efficiency and decrease reconciliation issues and the misplacement of products. RFID Journal (11/20) LinkedInFacebookTwitterEmail this Story
Quotient is on a roll with new FDA approvals & GPO contracts
More good news from Quotient! Not only do we have FDA-approved Reagent Red Blood Cells products, but also just approved Rare Antisera, including Anti-s and Anti-Wra. We also have new 3-yr agreements with Premier Inc. and the General Services Administration. Great products and value from the one manufacturer focused on manual testing. Contact us today.

  Science & Health 
  • Muscle regeneration therapy might prevent amputations
    Researchers at the Wake Forest Institute for Regenerative Medicine are working on an oxygen gel that can be injected into wounded muscles to sustain tissue and limbs and perhaps lives. Eventually, the technique could be used with bone, skin, ligament and tendon in complex regenerative treatments. The research is part of a larger program to treat battlefield injuries. WFMY-TV (Greensboro, N.C.) (11/16) LinkedInFacebookTwitterEmail this Story
Clinical Research: Understanding the Methodology Toolbox
Clinical Research: Understanding the Methodology Toolbox compiles articles of evidence-based research for use as an educational resource for those involved in clinical research, healthcare professionals and trainees in transfusion medicine and other medical specialties. Now in the AABB Marketplace.

  Emerging Trends 
  • Possible MS treatment disguises myelin molecules as red blood cells
    In patients with multiple sclerosis, the immune system identifies myelin, which insulates nerves and promotes nerve cell communication, as a foreign substance and eliminates it. Researchers found that when myelin molecules were attached to biodegradable nanoparticles and injected into the blood of mice, the macrophages treated them as dying red blood cells and appeared to signal other parts of the immune system to tolerate myelin. The findings were published in Nature Biotechnology. New Scientist (11/20) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  • Organovo advances 3D biologic printing
    Organovo is developing 3D printing of tissues and organs for drug development as well as for therapeutic use. "I can tell you that we are progressing active research in the areas of liver, blood vessel, bone and cartilage, cardiac and kidney," said Michael Renard, the San Diego-based company's executive vice president of commercial operations. (11/19) LinkedInFacebookTwitterEmail this Story

Digi-Trax® is your source for ISBT 128 labels
For labels that withstand the rigors of blood banking, look to our large selection of stock labels that meet FDA requirements for durability and readability. We have label materials for every budget. Need a unique label? We produce custom labels and offer on-demand printing solutions. And, as a full service provider, we provide validation services if needed. Learn more.

  Government & Regulatory 
  • Blood cell preparation device lands wider EU approval
    European regulators have granted Harvest Technologies broader approval for its SmartPReP 2 Bone Marrow Aspiration Concentration System. The device is now approved for processing concentrated blood cells at the point of care to be used in patients with end-stage critical limb ischemia. Mass High Tech (Boston) (11/19) LinkedInFacebookTwitterEmail this Story
  • Blood thinner apixaban wins expanded EU approval
    Apixaban received approval from the European Commission for stroke and blood clot prevention in patients with atrial fibrillation. The OK is apixaban's first for the indication. The FDA is expected to decide on an application for the same condition by March 17. Reuters (11/20) LinkedInFacebookTwitterEmail this Story
  Association News 
  • Hospitals encouraged to inform AABB of their participation in NHSN Hemovigilance Module
    Hospitals are encouraged to inform AABB of their participation in the Hemovigilance Module of the CDC's National Healthcare Safety Network. The CDC does not identify participating institutions due to the confidentiality rules to which it must adhere. Hospitals that identify themselves to AABB will be invited to join AABB's Hemovigilance Module Transfusion Safety Group. Staff of AABB's Patient and Donor Safety Center, working with additional experts, will analyze the group's hemovigilance data with the goal of developing interventions that will improve patient safety at the individual institutions and nationwide. Contact AABB's Patient and Donor Safety Center at (301) 215-6588 or by e-mail. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

  Editor's Note 
  • SmartBrief will not publish Thursday and Friday
    In observance of Thanksgiving in the U.S., SmartBrief will not be published Thursday and Friday. Publication will resume Monday. Enjoy the holiday! LinkedInFacebookTwitterEmail this Story
Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
VP Patient ServicesBlood Centers of the PacificUS - CA - San Francisco
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Director, LaboratorySan Diego Blood BankUS - CA - San Diego
Help Desk SpecialistAABBUS - MD
Click here to view more job listings.

If the only prayer you said in your whole life was 'thank you,' that would suffice."
--Meister Eckhart,
German theologian and philosopher

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information